OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $47.73 +0.09 (+0.19%) As of 09/3/2026 10:06 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC FilingsShort Interest About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$47.64▼$47.7350-Day Range$42.11▼$52.6852-Week Range$35.93▼$83.12Volume2,035 shsAverage Volume611 shsMarket Capitalization$3.41 billionP/E Ratio7.92Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited. Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access. Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.AI Generated. May Contain Errors. Read More Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLDPF Stock News HeadlinesZealand Pharma - Transactions related to share buy-back program (week 34, 2026)August 24, 2026 | markets.businessinsider.comZealand Pharma â Notification of holding of treasury sharesAugust 24, 2026 | markets.businessinsider.comThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.September 4 at 1:00 AM | Behind the Markets (Ad)Zealand Pharma A/SAugust 20, 2026 | barrons.comZealand Pharma - Transactions related to share buy-back program (week 33, 2026)August 17, 2026 | markets.businessinsider.comZealand Pharma A/S (ZLDPY) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | seekingalpha.comZealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830July 29, 2026 | tipranks.comZealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590July 24, 2026 | tipranks.comSee More Headlines ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $72.8675 at the beginning of the year. Since then, ZLDPF stock has decreased by 34.5% and is now trading at $47.73. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its earnings results on Thursday, May, 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. The firm had revenue of $5.33 million for the quarter, compared to analysts' expectations of $2.81 million. Zealand Pharma A/S had a trailing twelve-month return on equity of 18.53% and a net margin of 58.86%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today9/04/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CIK2068427 Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year Founded1998Profitability EPS (Trailing Twelve Months)$6.03 Trailing P/E Ratio7.92 Forward P/E Ratio13.08 P/E GrowthN/ANet Income$977.29 million Net Margins58.86% Pretax Margin74.39% Return on Equity18.53% Return on Assets17.14% Debt Debt-to-Equity Ratio0.02 Current Ratio37.17 Quick Ratio37.17 Sales & Book Value Annual Sales$1.40 billion Price / Sales2.45 Cash Flow$13.83 per share Price / Cash Flow3.45 Book Value$31.61 per share Price / Book1.51Miscellaneous Outstanding Shares71,526,000Free FloatN/AMarket Cap$3.41 billion OptionableNot Optionable Beta0.89 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:ZLDPF) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMan Who Called SpaceX Rise Says Elon’s NEW Project is Even BiggerJames Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...Paradigm Press | SponsoredHalf the market is standing on a trapdoorNearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...Behind the Markets | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | SponsoredThis Overlooked Fund Turns AI Stocks Into Weekly IncomeA small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...Investors Alley | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZLDPF Stock Alerts